Quarterly report pursuant to Section 13 or 15(d)

Revenue - Revenue From Licensing Agreements and Strategic Partnerships (Details)

v3.22.2
Revenue - Revenue From Licensing Agreements and Strategic Partnerships (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Mar. 31, 2021
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Disaggregation of Revenue [Line Items]          
Total revenue   $ 3,698 $ 3,285 $ 14,686 $ 18,918
Seagen          
Disaggregation of Revenue [Line Items]          
Total revenue   2,607 338 2,919 704
AstraZeneca          
Disaggregation of Revenue [Line Items]          
Total revenue $ 13,000 (130) 2,202 4,623 16,702
Servier          
Disaggregation of Revenue [Line Items]          
Total revenue   230 745 4,964 1,512
Genentech          
Disaggregation of Revenue [Line Items]          
Total revenue   $ 991 $ 0 $ 2,180 $ 0